175 related articles for article (PubMed ID: 37627268)
1. Aggregation-Inhibiting scFv-Based Therapies Protect Mice against AAV1/2-Induced A53T-α-Synuclein Overexpression.
Schlichtmann BW; Palanisamy BN; Malovic E; Nethi SK; Padhi P; Hepker M; Wurtz J; John M; Ban B; Anantharam V; Kanthasamy AG; Narasimhan B; Mallapragada SK
Biomolecules; 2023 Jul; 13(8):. PubMed ID: 37627268
[TBL] [Abstract][Full Text] [Related]
2. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
3. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
Maki RA; Holzer M; Motamedchaboki K; Malle E; Masliah E; Marsche G; Reynolds WF
Free Radic Biol Med; 2019 Sep; 141():115-140. PubMed ID: 31175983
[TBL] [Abstract][Full Text] [Related]
4. Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson's disease mice.
Karikari AA; McFleder RL; Ribechini E; Blum R; Bruttel V; Knorr S; Gehmeyr M; Volkmann J; Brotchie JM; Ahsan F; Haack B; Monoranu CM; Keber U; Yeghiazaryan R; Pagenstecher A; Heckel T; Bischler T; Wischhusen J; Koprich JB; Lutz MB; Ip CW
Brain Behav Immun; 2022 Mar; 101():194-210. PubMed ID: 35032575
[TBL] [Abstract][Full Text] [Related]
5. Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model.
Eteläinen TS; Kilpeläinen TP; Ignatius A; Auno S; De Lorenzo F; Uhari-Väänänen JK; Julku UH; Myöhänen TT
Neuropharmacology; 2022 Nov; 218():109213. PubMed ID: 35964686
[TBL] [Abstract][Full Text] [Related]
6. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
[TBL] [Abstract][Full Text] [Related]
7. Administration of AAV-Alpha Synuclein NAC Antibody Improves Locomotor Behavior in Rats Overexpressing Alpha Synuclein.
Chen YH; Wu KJ; Hsieh W; Harvey BK; Hoffer BJ; Wang Y; Yu SJ
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34205689
[TBL] [Abstract][Full Text] [Related]
8. A Single Chain Fragment Variant Binding Misfolded Alpha-Synuclein Exhibits Neuroprotective and Antigen-Specific Anti-Inflammatory Properties.
Fassler M; Benaim C; George J
Cells; 2022 Nov; 11(23):. PubMed ID: 36497081
[TBL] [Abstract][Full Text] [Related]
9. Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain.
Delenclos M; Faroqi AH; Yue M; Kurti A; Castanedes-Casey M; Rousseau L; Phillips V; Dickson DW; Fryer JD; McLean PJ
Acta Neuropathol Commun; 2017 Jun; 5(1):51. PubMed ID: 28645308
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of α-Synuclein Protein Levels by an Intracellular Single-Chain Antibody.
Chen YH; Yu SJ; Wu KJ; Wang YS; Tsai HM; Liao LW; Chen S; Hsieh W; Chen H; Hsu SC; Chen ML; Hoffer BJ; Wang Y
J Parkinsons Dis; 2020; 10(2):573-590. PubMed ID: 32176654
[TBL] [Abstract][Full Text] [Related]
11. Transmissible α-synuclein seeding activity in brain and stomach of patients with Parkinson's disease.
Thomzig A; Wagenführ K; Pinder P; Joncic M; Schulz-Schaeffer WJ; Beekes M
Acta Neuropathol; 2021 Jun; 141(6):861-879. PubMed ID: 33895878
[TBL] [Abstract][Full Text] [Related]
12. Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.
Musacchio T; Rebenstorff M; Fluri F; Brotchie JM; Volkmann J; Koprich JB; Ip CW
Ann Neurol; 2017 Jun; 81(6):825-836. PubMed ID: 28470693
[TBL] [Abstract][Full Text] [Related]
13. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
14. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.
Koprich JB; Johnston TH; Huot P; Reyes MG; Espinosa M; Brotchie JM
PLoS One; 2011 Mar; 6(3):e17698. PubMed ID: 21408191
[TBL] [Abstract][Full Text] [Related]
15. Peptide immunization against the C-terminal of alpha-synuclein reduces locomotor activity in mice overexpressing alpha-synuclein.
Chiu YS; Wu KJ; Yu SJ; Wu KL; Wang YS; Lin J; Chu CY; Chen S; Chen H; Hsu SC; Wang Y; Chen YH
PLoS One; 2023; 18(9):e0291927. PubMed ID: 37733672
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.
Martin LJ; Semenkow S; Hanaford A; Wong M
Neurobiol Aging; 2014 May; 35(5):1132-52. PubMed ID: 24325796
[TBL] [Abstract][Full Text] [Related]
17. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
[TBL] [Abstract][Full Text] [Related]
18. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.
He Q; Koprich JB; Wang Y; Yu WB; Xiao BG; Brotchie JM; Wang J
Mol Neurobiol; 2016 May; 53(4):2258-68. PubMed ID: 25972237
[TBL] [Abstract][Full Text] [Related]
19. Chronic mild stress accelerates the progression of Parkinson's disease in A53T α-synuclein transgenic mice.
Wu Q; Yang X; Zhang Y; Zhang L; Feng L
Exp Neurol; 2016 Nov; 285(Pt A):61-71. PubMed ID: 27637804
[TBL] [Abstract][Full Text] [Related]
20. E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease.
Sakai R; Suzuki M; Ueyama M; Takeuchi T; Minakawa EN; Hayakawa H; Baba K; Mochizuki H; Nagai Y
PLoS One; 2019; 14(6):e0218261. PubMed ID: 31242217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
